Interestingly, Amato et al. described EPHA2 overexpression in erlotinib-resistant LC cells, and suggested loss of EPHA2 after genetic ablation in vitro and gene targeting in vivo, to account for apoptosis induction, decreased proliferation, as well as LC growth repression. This evidence concerns the gene EPHA2 and laryngotracheoesophageal cleft.